The new CFO brings extensive experience in finance and business development at life science, pharma and technology companies.
HEIDELBERG, Germany, March 22, 2022 / B3C newswire / -- Torsten Buergermeister has been appointed Chief Financial Officer (CFO) of VERAXA Biotech, based in Heidelberg, Germany. Buergermeister joins VERAXA from Molecular Health, an international Precision Medicine company where he had global responsibilities as Senior Vice President of Finance.
“Torsten brings excellent financial managing skills with a very good knowledge of biotech and related capital markets,” said Dr. Christoph Antz, CEO of VERAXA. “We are excited to have him join our management team.”
About VERAXA Biotech
VERAXA’S mission is to tackle two of the biggest challenges in antibody drug development: Antibody discovery and ADC development. The company’s droplet-based microfluidic screening technology and its innovative antibody and protein conjugation technology allows for a rapid generation of antibodies against most complex target molecules and for a target product profile sharpening of existing monoclonal antibody candidates in oncology or precision medicine. VERAXA Biotech GmbH is a fusion of Velabs Therapeutics GmbH and Araxa Biosciences GmbH, both spin-off companies from European Molecular Biology Laboratory (EMBL), Europe’s most renowned institute for life science research and instrument development. VERAXA is a preferred license and cooperation partner of global biotech and pharma industries.
Contact
VERAXA Biotech GmbH
Dr. Christoph Antz
CEO
Meyerhofstrasse 1
69117 Heidelberg, Germany
+49-6221-387-8194
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: High-Throughput Screening Assays; Mass Screening; Immunoconjugates; Microfluidics; Precision Medicine; Antibodies, Monoclonal; Drug Screening Assays, Antitumor; Computational Biology; Fluorescence; Microscopy; Biological Science Disciplines; Biotechnology; Germany
Published by B3C newswire